Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial

European Heart Journal

Volumn 26, Issue 17, 2005, Pages 1712-1718

  Bonnefoy, Eric ^a   Steg, Philippe Gabriel ^b   Chabaud, Sylvie ^c   Dubien, Pierre Yves ^d   Lapostolle, Frédéric ^e   Boudet, Frédéric ^f   Lacroute, Jean Michel ^g   Dissait, Frederic ^h   Vanzetto, Gérald ⁱ   Leizorowicz, Alain ^c   Touboul, Paul ^a  

^a LOUIS PRADEL HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d SAMU 69   (France)

^e SAMU 93   (France)

^f SAMU 31   (France)

^g SAMU 38   (France)

^h SAMU 63   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute myocardial infarction; Diabetes; Fibrinolysis; Primary angioplasty; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETIC ANGIOPATHIES; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20844446144     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi269     Document Type: Article

References (21)

1. Woodfield SL, Lundergan CF, Reiner JS et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996;28:1661-1669.
2. FTT. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-322.
3. Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1997;30:171-179.
4. EMIP. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N Engl J Med 1993;329:383-389.
5. Hsu LF, Mak KH, Lau KW et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart 2002;88:260-265.
6. Harjai KJ, Stone GW, Boura J et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2003;91:1041-1045.
7. Hasdai D, Granger CB, Srivatsa SS et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy. Global use of strategies to open occluded arteries in acute coronary syndromes. J Am Coll Cardiol 2000;35:1502-1512.
8. Bonnefoy E, Lapostolle F, Leizorovicz A et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-829.
9. Thomas K, Ottervanger JP, de Boer MJ et al. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care 1999;22:647-649.
10. Grassman ED, Johnson SA, Krone RJ. Predictors of success and major complications for primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. An analysis of the 1990 to 1994 Society for Cardiac Angiography and Interventions Registries. J Am Coll Cardiol 1997;30:201-208.
11. Wu AH, Parsons L, Every NR et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002;40:1389-1394.
12. Hannan EL, Racz MJ, Arani DT et al. A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement. J Am Coll Cardiol 2000;36:395-403.
13. Laskey WK, Selzer F, Vlachos HA et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2002;90:1062-1067.
14. Waldecker B, Waas W, Haberbosch W et al. Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus nondiabetic patients. Diabetes Care 1999;22:1832-1838.
15. Piemontino U, Ceriello A, Di Minno G. Hemostatic and metabolic abnormalities in diabetes mellitus. The search for a link. Haematologica 1994;79:387-392.
16. Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-925.
17. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/ IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
18. Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 2003;63:1121-1163.
19. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-2484.
20. Kleiman NS, Lincoff AM, Kereiakes DJ et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998;97:1912-1920.
21. Steg PG, Bonnefoy E, Chabaud S et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-2856.